JPRN-jRCT2051220152
Recruiting
Phase 1
A clinical trial of STN1014100 ophthalmic solution in healthy adult male volunteers and dry eye patients for single and repeated dose - Phase I/IIa, clinical pharmacology study, exploratory study
Koji Oka0 sites134 target enrollmentJanuary 18, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Koji Oka
- Enrollment
- 134
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •\- Male or Female
- •\- Both eyes diagnosed as having dry eye
Exclusion Criteria
- •\- Any corneal and conjunctival abnormalities or other diseases other than dry eye affecting the ocular surface
- •\- Having eye disease requiring treatment other than dry eye.
- •\- Anatomically and functionally abnormal eyelids (e.g. Eyelid closure failure)
- •\- Anyone otherwise considered unsuitable for the study by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase I study of STN1013400 ophthalmic solution in healthy adult male volunteerMyopiaJPRN-jRCT2031210208Migita Yukie48
Completed
Phase 1
A phase I study of STN1013600 ophthalmic solution in healthy adult male volunteerPresbyopiaJPRN-jRCT2031210614Migita Yukie24
Completed
Phase 1
Pharmacokinetic study of STN1012600 ophthalmic solution in healthy adult males volunteersJPRN-jRCT2051230035Koji Oka8
Completed
Phase 2
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)Fuchs Endothelial Corneal DystrophyNCT05376176Santen Inc.86
Completed
Phase 2
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaPresbyopiaNCT05665387Santen Inc.79